Show me the data: U.S. doctors skeptical of reported COVID breakthrough
Send a link to a friend
[June 17, 2020]
By Michael Erman and Julie Steenhuysen
(Reuters) - The report on Tuesday of a
powerful treatment for the new coronavirus brought skepticism along with
optimism among U.S. doctors, who said the recent withdrawal of an
influential COVID-19 study left them wanting to see more data.
Global pressure to find a cure or vaccine has accelerated the process of
reporting coronavirus study results, feeding confusion over whether
therapies have been proven effective. One influential COVID study was
withdrawn this month by respected British medical journal The Lancet
over data concerns.
Researchers in Britain said dexamethasone, used to fight inflammation in
other diseases, reduced death rates of the most severely ill COVID-19
patients by around a third, and they would work to publish full details
as soon as possible.
But hours later South Korea's top health official cautioned about the
use of the drug for COVID-19 patients due to potential side effects.
"We have been burned before, not just during the coronavirus pandemic
but even pre-COVID, with exciting results that when we have access to
the data are not as convincing," said Dr. Kathryn Hibbert, director of
the medical intensive care unit at Harvard's Massachusetts General
Hospital.
Hibbert said published data would help her evaluate the findings and see
which patients benefited the most and at what dose.
"I am very hopeful this is true because it would be a huge step forward
in being able to help our patients," she said, but added she would not
change practice at this point.
[to top of second column]
|
A pharmacist displays an ampoule of Dexamethasone at the Erasme
Hospital amid the coronavirus disease (COVID-19) outbreak, in
Brussels, Belgium, June 16, 2020. REUTERS/Yves Herman
Steroids can suppress immune systems, warned Dr. Thomas McGinn,
deputy physician-in-chief at New York's largest healthcare system,
Northwell Health where, he told Reuters, physicians are using
steroids on a case-by-case basis.
"We have to see what the study looks like given the current
environment of retractions," said McGinn. "I just wait to see the
real data, see if it's peer reviewed and gets published in a real
journal, he said.
University of Washington professor of medicine Dr Mark Wurfel urged
the researchers to put out data before official publication.
"That would be very, very helpful in terms of helping us align our
patient populations with theirs and decide whether it's appropriate
to apply this therapy to our patients."
(Additional reporting by Sangmi Cha in Seoul; Writing by Peter
Henderson; Editing by David Gregorio and Giles Elgood)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|